Pazopanib (VOTRIENT FCT) Tablet
$869.00
VOTRIENT FCT Tablet offers a targeted therapeutic approach for patients with advanced renal cell carcinoma and soft tissue sarcoma, providing a valuable treatment option to help manage these challenging malignancies.
Description
VOTRIENT FCT Tablet contains Pazopanib in strengths of 200mg and 400mg, serving as a targeted therapy medication used primarily in the treatment of certain types of cancer, including advanced renal cell carcinoma (kidney cancer) and advanced soft tissue sarcoma.
Key Features:
- Targeted Therapy: VOTRIENT FCT Tablet contains Pazopanib, a tyrosine kinase inhibitor that selectively targets and inhibits multiple receptor tyrosine kinases involved in tumor growth and angiogenesis, thereby slowing cancer progression.
- Multiple Strengths: Available in two strengths (200mg and 400mg), facilitating individualized dosing based on factors such as disease stage, patient tolerance, and response to treatment.
- Renal Cell Carcinoma Treatment: VOTRIENT FCT is indicated for the first-line treatment of advanced renal cell carcinoma, offering patients a therapeutic option to help manage this aggressive form of kidney cancer.
- Soft Tissue Sarcoma Treatment: Additionally, VOTRIENT FCT is approved for the treatment of advanced soft tissue sarcoma in patients who have received prior chemotherapy, providing an alternative treatment option for this rare malignancy.
- Oral Administration: Administered orally as a tablet, VOTRIENT FCT offers convenient dosing and improved patient compliance compared to intravenous therapies.
- Angiogenesis Inhibition: By inhibiting angiogenesis, the formation of new blood vessels necessary for tumor growth and metastasis is disrupted, leading to tumor shrinkage and potential disease stabilization.
- Potential Adverse Effects: Common side effects of VOTRIENT FCT may include fatigue, diarrhea, hypertension, nausea, and hair color changes. Patients should be monitored closely for adverse reactions and managed accordingly.
- Individualized Treatment Approach: The selection of the appropriate VOTRIENT FCT dosage and treatment duration should be based on factors such as disease characteristics, patient’s overall health status, and treatment response.
Additional information
| Strength | 200mg, 400mg |
|---|
Only logged in customers who have purchased this product may leave a review.
Related products
Select options
This product has multiple variants. The options may be chosen on the product page
Select options
This product has multiple variants. The options may be chosen on the product page
Select options
This product has multiple variants. The options may be chosen on the product page
Select options
This product has multiple variants. The options may be chosen on the product page
Select options
This product has multiple variants. The options may be chosen on the product page
Select options
This product has multiple variants. The options may be chosen on the product page
Reviews
There are no reviews yet.